{"id":51351,"date":"2023-05-12T10:41:45","date_gmt":"2023-05-12T05:11:45","guid":{"rendered":"http:\/\/finservwealth.com\/dr-lal-pathlabs-stock-under-pressure-after-march-quarter-earnings-fails-to-impress\/"},"modified":"2023-05-12T10:41:45","modified_gmt":"2023-05-12T05:11:45","slug":"dr-lal-pathlabs-stock-under-pressure-after-march-quarter-earnings-fails-to-impress","status":"publish","type":"post","link":"https:\/\/finservwealth.com\/hi\/dr-lal-pathlabs-stock-under-pressure-after-march-quarter-earnings-fails-to-impress\/","title":{"rendered":"Dr Lal PathLabs stock under pressure after March quarter earnings fails to impress"},"content":{"rendered":"<p> Dr Lal PathLabs Ltd reported 8.2 percent year on year decline in net profit for the March quarter to Rs 57 crore from Rs 62 crore. Revenue rose just 1.1 percent to Rs 491 crore from a year ago.<\/p><div id=\"finse-1569758984\" class=\"finse-content finse-entity-placement\"><script async src=\"\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-9118214110898834\" crossorigin=\"anonymous\"><\/script><ins class=\"adsbygoogle\" style=\"display:block;\" data-ad-client=\"ca-pub-9118214110898834\" \ndata-ad-slot=\"\" \ndata-ad-format=\"auto\"><\/ins>\n<script> \n(adsbygoogle = window.adsbygoogle || []).push({}); \n<\/script>\n<\/div>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/dr-lal-pathlabs-stock-under-pressure-after-march-quarter-earnings-fails-to-impress_16997481.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0Dr Lal PathLabs Ltd reported 8.2 percent year on year decline in net profit for the March quarter to Rs 57 crore from Rs 62 crore. Revenue rose just 1.1 percent to Rs 491 crore from a year ago. Dr Lal PathLabs Ltd reported 8.2 percent year on year decline in net profit for the March quarter to Rs 57 crore from Rs 62 crore. Revenue rose just 1.1 percent to Rs 491 crore from a year ago.\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/dr-lal-pathlabs-stock-under-pressure-after-march-quarter-earnings-fails-to-impress_16997481.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<p> Dr Lal PathLabs Ltd reported 8.2 percent year on year decline in net profit for the March quarter to Rs 57 crore from Rs 62 crore. Revenue rose just 1.1 percent to Rs 491 crore from a year ago.<\/p>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/dr-lal-pathlabs-stock-under-pressure-after-march-quarter-earnings-fails-to-impress_16997481.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0Dr Lal PathLabs Ltd reported 8.2 percent year on year decline in net profit for the March quarter to Rs 57 crore from Rs 62 crore. Revenue rose just 1.1 percent to Rs 491 crore from a year ago. Dr Lal PathLabs Ltd reported 8.2 percent year on year decline in net profit for the March quarter to Rs 57 crore from Rs 62 crore. Revenue rose just 1.1 percent to Rs 491 crore from a year ago.\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/dr-lal-pathlabs-stock-under-pressure-after-march-quarter-earnings-fails-to-impress_16997481.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>\n<p><!-- \/wp:html --> Dr Lal PathLabs Ltd reported 8.2 percent year on year decline in net profit for the March quarter to Rs 57 crore from Rs 62 crore. Revenue rose just 1.1 percent to Rs 491 crore from a year ago.<\/p>","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","_themeisle_gutenberg_block_has_review":false,"footnotes":""},"categories":[70],"tags":[],"class_list":["post-51351","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-latest-news"],"jetpack_featured_media_url":"https:\/\/www.moneycontrol.com\/news_image_files\/2019\/200x200\/d\/dr-lalpathlabs-pvt-ltd_200.jpg","_links":{"self":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/51351","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/comments?post=51351"}],"version-history":[{"count":0,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/51351\/revisions"}],"wp:attachment":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/media?parent=51351"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/categories?post=51351"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/tags?post=51351"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}